- Building a Protocol Expressway: The Case of Mayo Clinic Cancer Center
[作者：McJoynt, TA; Hirzallah, MA; Satele, DV; Pitzen, JH; Alberts, SR; Rajkumar, SV,期刊：Journal of clinical oncology, 页码：3855-3860 , 文章类型： Article，,卷期：2009年27-23]
- PurposeInconsistencies and errors resulting from nonstandard processes, together with redundancies, rework, and excess workload, lead to extended time frames for clinical trial protocol development. This results in dissa...
- Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma
[作者：Clarke, JL; Iwamoto, FM; Sul, J; Panageas, K; Lassman, AB; DeAngelis, LM; Hormigo, A; Nolan, CP; Gavrilovic, I; Karimi, S; Abrey, LE,期刊：Journal of clinical oncology, 页码：3861-3867 , 文章类型： Article，,卷期：2009年27-23]
- PurposeAlternative dosing schedules of temozolomide may improve survival in patients with newly diagnosed glioblastoma (GBM) by increasing the therapeutic index, overcoming common mechanisms of temozolomide resistance, o...
- American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
[作者：Meropol, NJ; Schrag, D; Smith, TJ; Mulvey, TM; Langdon, RM; Blum, D; Ubel, PA; Schnipper, LE,期刊：Journal of clinical oncology, 页码：3868-3874 , 文章类型： Article，,卷期：2009年27-23]
- Advances in early detection, prevention, and treatment have resulted in consistently falling cancer death rates in the United States. In parallel with these advances have come significant increases in the cost of cancer ...
- Risk of Bilateral Renal Cell Cancer
[作者：Wiklund, F; Tretli, S; Choueiri, TK; Signoretti, S; Fall, K; Adami, HO,期刊：Journal of clinical oncology, 页码：3737-3741 , 文章类型： Article，,卷期：2009年27-23]
- PurposeThe risk of developing bilateral kidney cancer has not been adequately defined in any large, population-based study with long-term follow-up to our knowledge.Patients and MethodsWe estimated the risk of metachrono...
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
[作者：Attard, G; Reid, AHM; A'Hern, R; Parker, C; Oommen, NB; Folkerd, E; Messiou, C; Molife, LR; Maier, G; Thompson, E; Olmos, D; Sinha, R; Lee, G; Dowsett, M; Kaye, SB; Dearnaley, D; Kheoh, T; Molina, A; de Bono, JS,期刊：Journal of clinical oncology, 页码：3742-3748 , 文章类型： Article，,卷期：2009年27-23]
- PurposeIt has been postulated that castration-resistant prostate cancer (CRPC) commonly remains hormone dependent. Abiraterone acetate is a potent, selective, and orally available inhibitor of CYP17, the key enzyme in an...
- Randomized Double-Blind 2 X 2 Trial of Low-Dose Tamoxifen and Fenretinide for Breast Cancer Prevention in High-Risk Premenopausal Women
[作者：Decensi, A; Robertson, C; Guerrieri-Gonzaga, A; Serrano, D; Cazzaniga, M; Mora, S; Gulisano, M; Johansson, H; Galimberti, V; Cassano, E; Moroni, SM; Formelli, F; Lien, EA; Pelosi, G; Johnson, KA; Bonanni, B,期刊：Journal of clinical oncology, 页码：3749-3756 , 文章类型： Article，,卷期：2009年27-23]
- PurposeTamoxifen and fenretinide are active in reducing premenopausal breast cancer risk and work synergistically in preclinical models. The authors assessed their combination in a two-by-two biomarker trial.Patients and...
|